Influenza vaccination has a potential protective effect against adverse events within 120 days of a positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) diagnosis, according to a study published online Aug. 3 in PLOS ONE.
The Paradigm Cancer Diagnostic (PCDx) testing is certified under the Clinical Laboratory Improvement Amendments (CLIA) and Paradigm has also been awarded accreditation by the College of American Pathologists (CAP).